Real-World Assessment of Therapeutic Strategies and Survival Outcomes Following First-Line Tislelizumab Therapy in Advanced Non-Small Cell Lung Cancer

Enrolling by invitationOBSERVATIONAL

Enrollment

500

Participants

Timeline

Start Date

August 16, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2026

Conditions

Non-Small-Cell Lung CancerNon-Small-Cell Lung Cancer Stage IV

Trial Locations (1)

Shanghai Chest Hospital, Shanghai

All Listed Sponsors

lead

Shanghai Chest Hospital

OTHER